Atara Biotherapeutics, Inc. $ATRA

What the company doesAI summary of filing

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its EBV-specific T-cell platform. The company's primary commercial product is tab-cel (Ebvallo), an EBV-specific T-cell immunotherapy approved in the European Economic Area, United Kingdom, and Switzerland for EBV-positive post-transplant lymphoproliferative disease; tab-cel is in Phase 3 development in the U.S. and subject to a regulatory resubmission process following FDA feedback. The company generates revenue through its partnership with Pierre Fabre Medicament, which commercializes Ebvallo in Europe and worldwide territories, with Atara eligible to receive milestone payments and royalties on net sales. Atara is a clinical-stage, pre-revenue company focused on developing its lead product for regulatory approval, having paused CAR T development programs and substantially restructured its workforce in 2025. [10-K 2026-03-16]

Segments: tab-cel (Ebvallo) - EBV-specific T-cell immunotherapy, ATA3219 - allogeneic CD19 CAR T (development paused), ATA3431 - allogeneic bispecific CD19/CD20 CAR T (development discontinued), Tab-cel multi-cohort study - Phase 2 study for additional EBV-driven diseases